INTRODUCTION {#s1}
============

*BRCA1* and *BRCA2 (BRCA)* are rapidly evolving genes with high levels of variation across primate species \[[@R1]-[@R3]\]. Germline mutations in *BRCA* predispose individuals for breast and ovarian cancer \[[@R4]-[@R5]\]. Extensive efforts have been made to determine the prevalence and spectrum of germline mutations in both genes to aid clinical diagnosis of and prevent the disease \[[@R6]-[@R8]\].

Increasing evidence indicates that the presence of *BRCA* germline mutations in human familial breast and ovarian cancer is largely ethnic-specific \[[@R9]\]. For example, 185delAG \[c.66_67delAG according to human genome variation society (HGVS) nomenclature\] and 5382insC (c.5263_5264insC) in *BRCA1* and 6174delT (c.5946delT) in *BRCA2* are highly prevalent in Ashkenazi Jews \[[@R10]\]; c.4153delA (c.4035delA), C61G (c.-58C\>G), and 5382insC (c.5263_5264insC) in *BRCA1* are common in Polish familial breast cancer patients \[[@R11]\]; c.303T\>G, c.5324T\>G, c.1623dupG, and c.4122_4123delTG in *BRCA1* are frequently present in the familial breast cancer patients of African ancestry \[[@R12]\]; ex9-12del in *BRCA1* is often seen in Mexican familial breast and ovarian cancer patients \[[@R13]\], and c.7480C\>T in *BRCA2* is enriched in Korean familial breast cancer patients \[[@R14]\].

*BRCA* mutations have been extensively analyzed in European and North American populations, but much less are known about them in Asian, African, and Latin American populations, although these contribute most of the total human population. Using the data from Western populations to interpret *BRCA* mutations in non-Western patients can be inaccurate and lead to misdiagnoses. Therefore, knowledge of ethnic-specific *BRCA* mutations is urgently demanding and will be highly beneficial for the patients.

Mainland China has a population size of nearly 1.4 billion, accounting for one fifth of the human population worldwide. However, limited information about *BRCA* mutations in this large population is available in current *BRCA* variation databases. For example, only 13 of the 1,791 *BRCA1* variants and three of the 2,000 *BRCA2* variants in the Breast Cancer Information Core (BIC) database were derived exclusively from mainland Chinese patients \[[@R15]\]. We hypothesized that 1) *BRCA* variation may be common in this population, and 2) many variants representing potential mutations may have already been identified but this information is unknown outside the Chinese scientific community, because many Chinese scientists publish in Chinese rather than in English and most Chinese medical and health science journals are not included in international journal databases \[[@R16]\]. To test our hypothesis, we performed an extensive survey of Chinese and English scientific literature to collect *BRCA* variant data derived solely from mainland Chinese familial breast and ovarian cancer patients (Figure [1](#F1){ref-type="fig"}).

![Outline of the study\
It shows the steps taken to extract information about *BRCA* variation in mainland Chinese familial breast and ovarian cancer patients.](oncotarget-07-9600-g001){#F1}

RESULTS AND DISCUSSION {#s2}
======================

Identification of publications {#s2_1}
------------------------------

We identified 32 Chinese publications, including 24 peer-reviewed papers and eight graduate theses ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}), and 11 peer-reviewed English papers. This totaled 43 publications covering between 2003 and 2015 reported *BRCA* variants from mainland Chinese familial breast and ovarian cancer patients \[[@R17]-[@R59]\].

From these publications, we identified familial breast cancer cases using the inclusion criteria described in each publication: at least one first-degree relative with breast cancer irrespective of age; breast cancer diagnosed before the age of 35 years with a family history of breast and/or ovarian cancer; at least one or two first- or second-degree relatives diagnosed with breast cancer at any age; at least three relatives affected by breast cancer or breast and ovarian cancer; triple-negative breast cancer patients diagnosed before the age of 45 years; bilateral breast cancer diagnosed before the age of 50 years; one or more primary breast/ovarian cancers in first- or second-degree relatives; and at least one relative with cancer other than breast and ovarian cancer that is known to be *BRCA1*-related. From these publications, we also collected pedigree and genotype information available from family members although most publications only analyzed the proband without such information ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

We identified a total of 3,844 familial breast and ovarian cancer cases from the original studies. All of these were analyzed for *BRCA1* (3,129 covered all exons), and 3,024 were analyzed for *BRCA2* (2,854 covered all exons); 92% of the 3,844 cases were Han Chinese and the rest were from other ethnic groups (Hui, Mongol, Uyghur, Kazakh, and Russian) (Table [1](#T1){ref-type="table"}). These studies were performed in 15 provinces or cities in mainland China, mostly in the densely populated, economically advanced eastern coast area, with the exception of Xinjiang and Ningxia regions (Figure [2](#F2){ref-type="fig"}). The information highlights the need to analyze the population in so far uncovered regions to fully determine the prevalence and spectrum of *BRCA* mutations in the entire mainland Chinese population.

###### Publications reporting BRCA mutations in mainland Chinese patients

  Year    Location                      Ethnicity                             Cases   Targeted exons                                  Published in                  Methods[\*](#tfn_001){ref-type="table-fn"}   References       
  ------- ----------------------------- ------------------------------------- ------- ----------------------------------------------- ----------------------------- -------------------------------------------- ------------ --- ----
                                                                                      BRCA1                                           BRCA2                         Chinese                                      English          
  2003    Beijing                       Han                                   9       All                                                                           \+                                                        a   17
  2003    Beijing                       Han                                   26      All                                                                                                                        \+           a   18
  2003    Jiangsu                       Han                                   23      All but 1, 4                                                                  \+                                                        a   19
  2003    Shanghai                      Han                                   20      All                                                                                                                        \+           a   20
  2003    Beijing                       Han                                   15      4, 8, 11, 18, 19, 20                            All but 15, 16, 25, 26        \+                                                        b   21
  2004    Shanghai                      Han                                   645     All                                             All                                                                        \+           b   22
  2005    Shanghai                      Han                                   13      All                                             All                           \+                                                        a   23
  2005    Anhui                         Han                                   76      All but 1, 3, 4, 6, 7, 10, 14, 19, 21-24                                      \+                                                        a   24
  2006    Shanghai                      Han                                   35      All                                             All                           \+                                                        a   25
  2006    Shanghai                      Han                                   33      All                                             All                                                                        \+           a   26
  2007    Hebei                         Han                                   18      2, 11A, 11B, 20                                 Not specified 4 mutations     \+                                                        c   27
  2007    Shanghai Liaoning Shadong     Han                                   177     Not specified 7 mutations                                                     \+                                                        a   28
  2007    Shanghai Liaoning Shadong     Han                                   39      All                                                                           \+                                                        a   29
  2007    Shanghai Liaoning Shadong     Han                                   60      1100delAT, IVS17-1G\>T, IVS21+1G\>C, 5640delA                                 \+                                                        a   30
  2007    Shanghai Liaoning Shadong     Han                                   139     All                                             All                           \+                                                        a   31
  2007    Guangdong                     Han                                   17      All                                                                           \+                                                        a   32
  2008    Shanghai Liaoning Shandong    Han                                   115     All                                             All                           \+                                                        a   33
  2008    Shanghai Liaoning Shadong     Han                                   489     All                                             All                                                                        \+           d   34
  2008    Shandong                      Han                                   25      All                                             All                           \+                                                        a   35
  2008    Shanghai Guangdong Liaoning   Han                                   219     All                                             All                           \+                                                        a   36
  2009    Shandong                      Han                                   25      All                                                                           \+                                                        a   37
  2009    Beijing                       Han                                   139     All                                                                                                                        \+           a   38
  2009    Hunan                         Han                                   26      All                                             All                           \+                                                        a   39
  2009    Fujian                        Han                                   20      11                                                                            \+                                                        b   40
  2009    Tianjin                       Han                                   5       1, 11, 16, 20                                                                 \+                                                        a   41
  2009    Shandong                      Han                                   30      2, 20                                                                         \+                                                        a   42
  2010    Heilongjiang                  Han                                   54      All but 1, 4                                                                  \+                                                        c   43
  2011    Shandong                      Han                                   8       2, 11                                                                         \+                                                        b   44
  2012    Hebei                         Han                                   13      2, 11, 20                                       11                            \+                                                        c   45
  2012    Hebei                         Han                                   64      All                                             All                           \+                                                        a   46
  2012    Ningxia                       Hui                                   7       5, 11, 18, 20, 24                               10, 11                        \+                                                        b   47
  2012    Guangdong                     Han                                   92      All but 1, 4                                                                  \+                                                        b   48
  2012    Beijing                       Han                                   409     All                                             All                                                                        \+           b   49
  2012    Zhejiang                      Han                                   92      3, 8, 11, 12, 13, 24                            3, 5, 6, 10, 11, 18, 22, 23   \+                                                        b   50
  2013    Zhejiang                      Han                                   62      All                                             All                           \+                                                        b   51
  2013    Xinjiang                      Han                                   30      All                                             All                           \+                                                        a   52
  2013    Xinjiang                      Han                                   79      All                                             All                                                                        \+           a   53
  2014    Xinjiang                      Han Mongol Hui Uygur                  214     All                                             All                           \+                                                        a   54
  2014    Xinjiang                      Han                                   25      Not specified                                   Not specified                                                              \+           a   55
  2014    Shanghai                      Han                                   2       All                                             All                           \+                                                        e   56
  2015    Xinjiang                      Han Mongol Hui Uygur Kazakh Russian   82      All                                             All                           \+                                                        a   57
  2015    Beijing                       Han                                   109     All                                             All                                                                        \+           b   58
  2015    Shanghai                      Han                                   64      All                                             All                                                                        \+           e   59
  Total                                                                       3,844   3844                                            3024                          32                                           11               43

a\. DHPLC, Sanger sequencing; b. Sanger sequencing; c. SSCP, Sanger sequencing; d. SSCP, DHPLC, Sanger sequencing; e. NGS, Sanger sequencing

![Geographic locations of the original studies\
The original studies were performed in 15 provinces and cities in mainland China. Of these, 13 were in east coast area of Han Chinese and two were in Xinjiang and Ningxia of other ethnic groups.](oncotarget-07-9600-g002){#F2}

Multiple assays including hetero-duplex formation, single-strand conformation polymorphism (SSCP), denaturing high-performance liquid chromatography (DHPLC), and Sanger sequencing were used in the original studies. All *BRCA1* and *BRCA2* variants collected in our current study were identified by either direct Sanger sequencing or by Sanger sequencing validation for the results from other assays (Table [1](#T1){ref-type="table"}).

*BRCA* variants identified from publications {#s2_2}
--------------------------------------------

By mining the variant data from the 3,844 cases, we identified a total of 137 distinct *BRCA1* variants in 409 cases, and 80 distinct *BRCA2* variants in 157 cases (Table [2](#T2){ref-type="table"}, [Supplementary Table 3](#SD2){ref-type="supplementary-material"}; Table [3](#T3){ref-type="table"}, [Supplementary Table 4](#SD3){ref-type="supplementary-material"}). Of the 137 *BRCA1* variants, 33 (24.6%) were detected by at least two different studies; of the 80 *BRCA2* variants, 22 (27.2%) were detected by at least two different studies.

###### Examples of *BRCA1* variants identified in mainland Chinese familial breast and ovarian cancer patients[\*](#tfn_002){ref-type="table-fn"}

  Class (BIC)   Exon   HGVS annotation            Variation type                                        Total case   Carrier   
  ------------- ------ -------------------------- ----------------------------------------------------- ------------ --------- ----
                       cDNA                       Protein                                                                      
  Class 5       11A    c.981_982delAT             p.Cys328[\*](#tfn_002){ref-type="table-fn"}           Frameshift   1142      18
  Class 5       11A    c.1116G\>A                 p.Trp372[\*](#tfn_002){ref-type="table-fn"}           Nonsense     480       5
  Class 5       11B    c.2110_2111delAA           p.Asn704Cysfs[\*](#tfn_002){ref-type="table-fn"}7     Frameshift   822       8
  Class 5       11B    c.2275C\>T                 p.Gln759[\*](#tfn_002){ref-type="table-fn"}           Nonsense     473       5
  Class 5       11B    c.1556delA                 p.Lys519Argfs[\*](#tfn_002){ref-type="table-fn"}13    Frameshift   7         2
  Class 5       11B    c.2138C\>G                 p.Ser713[\*](#tfn_002){ref-type="table-fn"}           Nonsense     50        2
  Class 5       11D    c.3531delT                 p.Phe1177Leufs[\*](#tfn_002){ref-type="table-fn"}33   Frameshift   7         6
  Class 5       11D    c.3916_3917delTT           p.Leu1306Aspfs[\*](#tfn_002){ref-type="table-fn"}23   Frameshift   518       3
  Class 5       11D    c.3640G\>T                 p.Glu1214[\*](#tfn_002){ref-type="table-fn"}          Nonsense     239       3
  Class 5       11D    c.3607C\>T                 p.Arg1203[\*](#tfn_002){ref-type="table-fn"}          Nonsense     239       2
  Class 5       11D    c.4065_4068delTCAA         p.Asn1355Lysfs[\*](#tfn_002){ref-type="table-fn"}10   Frameshift   171       2
  Class 5       11D    c.3770_3771delAG           p.Glu1257Glyfs[\*](#tfn_002){ref-type="table-fn"}9    Frameshift   548       2
  Class 5       19     c.5154G\>A                 p.Trp1718[\*](#tfn_002){ref-type="table-fn"}          Nonsense     62        2
  Pending       I-5    c.212+1G\>T                \-                                                    IVS          214       3
  Pending       11A    c.1064A\>G                 p.Lys355Arg                                           Missense     92        8
  Pending       11B    c.2077G\>A                 p.Asp693Asn                                           Missense     214       3
  Pending       11B    c.1934C\>A                 p.Ser645Tyr                                           Missense     214       2
  Pending       11C    c.3113A\>G                 p.Glu1038Gly                                          Missense     437       31
  Pending       11C    c.3119G\>A                 p.Ser1040Asn                                          Missense     667       3
  Pending       11D    c.3548A\>G                 p.Lys1183Arg                                          Missense     439       34
  Pending       11D    c.3508A\>T                 p.Ile1170Phe                                          Missense     76        2
  Pending       I-16   c.4986+1G\>A               \-                                                    IVS          101       2
  Pending       16     c.4837A\>G                 p.Ser1613Gly                                          Missense     302       17
  Pending       22     c.5363G\>T                 p.Gly1788Val                                          Missense     548       2
  Pending       24     c.5470_5477delATTGGGCA     p.Ile1824Aspfs[\*](#tfn_002){ref-type="table-fn"}3    Frameshift   1505      20
  Pending       24     c.5521delA                 p.Ser1841Valfs[\*](#tfn_002){ref-type="table-fn"}2    Frameshift   1272      8
  Pending       24     c.5503C\>T                 p.Arg1835[\*](#tfn_002){ref-type="table-fn"}          Nonsense     173       2
  Novel         2      c.-1A\>T                   \-                                                    IVS          76        2
  Novel         11A    c.919A\>G                  p.Lys307Glu                                           Missense     92        10
  Novel         11A    c.1660G\>T                 p.Glu554[\*](#tfn_002){ref-type="table-fn"}           Nonsense     628       3
  Novel         11B    c.2073delA                 p.Arg691Serfs[\*](#tfn_002){ref-type="table-fn"}10    Frameshift   430       5
  Novel         11B    c.2248_2252delCTCAT        p.Leu750Valfs[\*](#tfn_002){ref-type="table-fn"}10    Frameshift   518       2
  Novel         11C    c.2572C\>T                 p.Gln858[\*](#tfn_002){ref-type="table-fn"}           Nonsense     782       4
  Novel         11C    c.3122C\>G                 p.Ser1041[\*](#tfn_002){ref-type="table-fn"}          Nonsense     743       4
  Novel         11C    c.2798_2799delGT           p.Gly933Alafs[\*](#tfn_002){ref-type="table-fn"}4     Missense     743       3
  Novel         11C    c.3294delT                 p.Pro1099Leufs[\*](#tfn_002){ref-type="table-fn"}10   Frameshift   239       3
  Novel         11C    c.2939T\>A                 p.Ile980Lys                                           Missense     214       2
  Novel         11C    c.2941C\>G                 p.Pro981Ala                                           Missense     214       2
  Novel         11C    c.2603C\>A                 p.Ser868[\*](#tfn_002){ref-type="table-fn"}           Nonsense     480       2
  Novel         11D    c.3363_3367delTACAG        p.Asn1121Lysfs[\*](#tfn_002){ref-type="table-fn"}10   Frameshift   1186      7
  Novel         11D    c.3359_3363delTTAAT        p.Val1120Aspfs[\*](#tfn_002){ref-type="table-fn"}11   Frameshift   1226      5
  Novel         11D    c.3432G\>C                 p.Gln1144His                                          Missense     7         3
  Novel         11D    c.3450delT                 p.Asp1151Metfs[\*](#tfn_002){ref-type="table-fn"}4    Frameshift   519       3
  Novel         11D    c.3952A\>C                 p.Ile1318Leu                                          Missense     20        2
  Novel         11D    c.3433delG                 p.Val1145Phefs[\*](#tfn_002){ref-type="table-fn"}10   Frameshift   7         2
  Novel         I-23   c.5468-1_5474delGCAATTGG   \-                                                    IVS          823       8

The table lists the variants detected in at least two cases in each class

###### Examples of *BRCA2* variants identified in mainland Chinese familial breast and ovarian cancer patients[\*](#tfn_003){ref-type="table-fn"}

  Class (BIC)   Exon   HGVS annotation       Variant type                                          Total cases   Carrier   
  ------------- ------ --------------------- ----------------------------------------------------- ------------- --------- ----
                       cDNA                  Protein                                                                       
  Class 5       3      c.262_263delCT        p.Leu88Alafs\*12                                      Frameshift    518       2
  Class 5       10     c.1832C\>A            p.Ser611[\*](#tfn_003){ref-type="table-fn"}           Nonsense      518       4
  Class 5       10     c.1399A\>T            p.Lys467[\*](#tfn_003){ref-type="table-fn"}           Nonsense      191       3
  Class 5       19     c.8485C\>T            p.Gln2829[\*](#tfn_003){ref-type="table-fn"}          Nonsense      99        2
  Class 5       11B    c.3195_3198delTAAT    p.Asn1066Leufs[\*](#tfn_003){ref-type="table-fn"}10   Frameshift    1226      5
  Class 5       11B    c.2808_2811delACAA    p.Ala938Profs[\*](#tfn_003){ref-type="table-fn"}21    Frameshift    708       2
  Class 5       11C    c.3744_3747delTGAG    p.Ser1248Argfs[\*](#tfn_003){ref-type="table-fn"}10   Frameshift    708       2
  Class 5       11D    c.5164_5165delAG      p.Ser1722Tyrfs[\*](#tfn_003){ref-type="table-fn"}4    Frameshift    518       4
  Class 5       11E    c.5576_5579delTTAA    p.Ile1859Lysfs[\*](#tfn_003){ref-type="table-fn"}3    Frameshift    1302      5
  Class 5       11E    c.5682C\>G            p.Tyr1894[\*](#tfn_003){ref-type="table-fn"}          Nonsense      99        2
  Class 5       11F    c.6591_6592delTG      p.Glu2198Asnfs[\*](#tfn_003){ref-type="table-fn"}4    Frameshift    409       3
  Class 5       23     c.9098_9099insA       p.Gln3034Serfs[\*](#tfn_003){ref-type="table-fn"}10   Frameshift    518       4
  Pending       10     c.865A\>C             p.Asn289His                                           Missense      321       13
  Novel         10     c.1303dupA            p.Arg435Lysfs[\*](#tfn_003){ref-type="table-fn"}17    Frameshift    708       2
  Novel         10     c.1881delA            p.Pro628Hisfs[\*](#tfn_003){ref-type="table-fn"}16    Frameshift    708       2
  Novel         11A    c.2442delC            p.Met815Trpfs[\*](#tfn_003){ref-type="table-fn"}10    Frameshift    708       2
  Novel         11E    c.5864C\>G            p.Ser1955[\*](#tfn_003){ref-type="table-fn"}          Nonsense      409       2
  Novel         11F    c.6645_6648CTCC       p.Tyr2215[\*](#tfn_003){ref-type="table-fn"}          Nonsense      375       3
  Novel         11F    c.6150_6151insT       p.Asn2051[\*](#tfn_003){ref-type="table-fn"}          Nonsense      109       2
  Novel         14     c.7142delC            p.Pro2381Hisfs[\*](#tfn_003){ref-type="table-fn"}13   Frameshift    99        5
  Novel         18     c.8172delG            p.Trp2725Glyfs[\*](#tfn_003){ref-type="table-fn"}8    Frameshift    109       3
  Novel         18     c.8234dupT            p.Thr2746Aspfs[\*](#tfn_003){ref-type="table-fn"}18   Frameshift    708       2
  Novel         19     c.8400_8403del4ins5   p.Phe2801Leufs[\*](#tfn_003){ref-type="table-fn"}10   Nonsense      409       2
  Novel         20     c.8517C\>A            p.Tyr2839[\*](#tfn_003){ref-type="table-fn"}          Nonsense      181       2
  Novel         22     c.8820_8823del        p.Gln2941Leufs[\*](#tfn_003){ref-type="table-fn"}34   Frameshift    1013      3
  Novel         22     c.8950delT            p.Ser2984Glnfs[\*](#tfn_003){ref-type="table-fn"}4    Frameshift    604       2
  Novel         23     c.9105dup             p.Gln3036Serfs[\*](#tfn_003){ref-type="table-fn"}8    Frameshift    109       4
  Novel         24     c.9253delA            p.Thr3085Glnfs[\*](#tfn_003){ref-type="table-fn"}19   Frameshift    375       3

The table lists the variants detected in at least two cases in each class

Prevalence assessment {#s2_3}
---------------------

The prevalence of the variant carriers was 10.6% (409/3,844) for *BRCA1* and 5.2% (157/3,024) for *BRCA2* (Of the 3,844 cases, all were used for *BRCA1*, but 3,024 were used for *BRCA2*). The total number of cases used for all exon analysis was 3,129 in *BRCA1* and 2,854 in *BRCA2*. Thus, the total number of cases in the *BRCA2* group accounted for 91.2% of the *BRCA1* (2,854/3,129). Therefore, the different prevalence of *BRCA1* and *BRCA2* variations is unlikely caused by the analysis of different cases in each group but instead reflects the fact that *BRCA1* has a higher prevalence than *BRCA2* in Chinese population. This pattern differs from that in the neighboring Korean population, which has a much higher prevalence of *BRCA2* variation than *BRCA1* variation \[[@R14]\]. The variation types included frameshift, nonsense, missense, and splicing changes. Majority of the variants except a few do not have frequency information in genome databases, indicating that the variants are mostly rare in human population ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}, [Supplementary Table 4](#SD3){ref-type="supplementary-material"}).

Exon distribution of *BRCA* variants between Chinese and other patient populations {#s2_4}
----------------------------------------------------------------------------------

We compared exon distribution frequencies of *BRCA* variations between mainland Chinese patients and other patient populations represented in the BIC database. We compared the ratios calculated as: number of variation cases in each exon / total number of variation cases in each data set. The total number of variation cases (entries) in the BIC dataset was 15,311 for *BRCA1* \[[@R61]\] and 14,914 for *BRCA2* \[[@R62]\]; the total number of variation cases in this study was 409 for *BRCA1* and 157 for *BRCA2*. The results showed that the distribution frequencies in 13 out of 24 *BRCA1* exons were significantly different between between mainland Chinese and BIC populations (Figure [3A](#F3){ref-type="fig"}). Variants in mainland Chinese were particularly lower in exons 2 and 20 but higher in exons 11A, 11C, and 11D (exon 11 is arbitrarily divided into 11A, 11B, 11C, and 11D by the BIC database because of its large size) and exon 24 than in other populations. The variants in *BRCA1* exons 11A, 11C, 11D and exon 24 occurred in 299 of the 409 (73.1%) Chinese *BRCA1-* variation cases. In *BRCA2*, the differences were smaller with only 6 out of 27 exons showed significant difference between mainland Chinese and BIC populations. Exon 10 was the highest in mainland Chinese with 44 of the 157 (28%) Chinese *BRCA2*-variation cases (Figure [3B](#F3){ref-type="fig"}). Therefore, *BRCA1* exon 11A, 11C, 11D, exon 24, and *BRCA2* exon 10 are the variation hot spots in mainland Chinese patients.

![Comparison of exon distribution frequencies of *BRCA* variation between mainland Chinese and BIC populations\
Relative ratios between these two datasets were used for the comparison (see text for the details). Chi square (*χ*^2^) and Fisher exact test were used for statistics analysis. "\*" refers to *p* \< 0.05 (actual P values listed in [Supplementary Table 5](#SD1){ref-type="supplementary-material"}). **A.** Variant distribution in *BRCA1*. **B.** Variant distribution in *BRCA2*.](oncotarget-07-9600-g003){#F3}

BIC-matched variants {#s2_5}
--------------------

Fifty-six (40.3%) *BRCA1* and 34 (42.5%) *BRCA2* variants exist in the BIC database (Figure [4](#F4){ref-type="fig"}). Of these, 27 *BRCA1* and 23 *BRCA2* variants are classified by BIC as Class 5 (Pathogenic), 27 *BRCA1* and 9 *BRCA2* variants as Pending \[most were variants of unknown significance (VUS)\], and two *BRCA1* and two *BRCA2* variants as Class 1 (Benign). The most common pathogenic *BRCA1* variant was c.981_982delAT (p.Cys328\*) in exon 11A (*n* = 18), confirming the previous observation in a smaller group of patients \[[@R30]\]. The frequency of this variant was substantially higher in mainland Chinese than in non-Chinese populations: 18 of 409 (4.4%) Chinese *BRCA1* variant carriers carried this variant, compared with only 18 of 15,311 (0.1%) *BRCA1* variant carriers in the BIC database. The most common *BRCA1* Pending variant was c.3548A\>G (p.Lys1183Arg) in exon 11D (*n* = 34; frequency in 1000 Genomes: 0.3526) and c.3113A\>G (p.Glu1038Gly) in exon 11C (*n* = 31, frequency in 1000 Genomes: 0.3357, in Han Chinese Beijing: 0.689). Three Pending variants \[c.5470_5477delATTGGGCA (p.Ile1824Aspfs\*3), c.5503C\>T (p.Arg1835\*)\] c.5521delA (p.Ser1841Valfs\*2) with high frequencies were located at exon 24, which contributes to the BRCT domain of BRCA1 (Figure [3A](#F3){ref-type="fig"}). The most common Pathogenic *BRCA2* variant was c.3195_3198delTAAT (p.Asn1066Leufs\*10) in exon 11B (*n* = 5) and c.5576_5579delTTAA (p.Ile1859Lysfs\*3) in exon 11E (*n* = 5), and the most common Pending variant was c.865A\>C (p.Asn289His) in exon 10 (*n* = 13; frequency in 1000 Genomes: 0.0737). Except for the *BRCA1* c.981_982delAT variant, other known pathogenic and Pending variants in either *BRCA1* or *BRCA2* are unlikely to be founder mutation candidates among mainland Chinese patients due to their lower prevalence or higher frequency in normal population.

![Matching *BRCA* variants to the BIC database\
The 137 *BRCA1* and 80 *BRCA2* distinct variants from mainland Chinese patients were compared with the 1,781 *BRCA1* and 2,000 *BRCA2* distinct variants in the BIC database. Of the Chinese variants, 56 *BRCA1* and 34 *BRCA2* variants were matched, whereas 82 *BRCA1* and 46 *BRCA2* variants were not.](oncotarget-07-9600-g004){#F4}

No variants were found to overlap with other ethnic-specific *BRCA* founder mutations, including *BRCA1* 185delAG (c.66_67delAG, HGVS nomenclature) and 5382insC (c.5263_5264insC) and *BRCA2* 6174delT (c.5946delT) in Ashkenazi Jews \[[@R10]\]; *BRCA1* c.4153delA (c.4035delA), C61G (c.-58C\>G), and 5382insC (c.5263_5264insC) in Poles \[[@R11]\]; *BRCA1* c.303T\>G, c.5324T\>G, c.1623dupG, and c.4122_4123delTG in Africans \[[@R12]\]; *BRCA1* ex9-12del in Mexicans \[[@R13]\], and BRCA2 c.7480C\>T in Koreans \[[@R14]\].

Novel *BRCA* variants {#s2_6}
---------------------

Eighty-one (59.4%) *BRCA1* variants and 46 (57.5%) *BRCA2* variants are not recorded in the BIC database (Figure [4](#F4){ref-type="fig"}). A total of 19 of these 81 *BRCA1* variants and 15 of the 46 *BRCA2* variants were detected in at least two cases, with c.919A\>G (p.Lys307Glu) in *BRCA1* exon 11A (*n* = 10), c.7142delC (p.Pro2381Hisfs\*13) in *BRCA2* exon 14 (*n* = 5) having the highest frequencies. We compared these novel variants with the *BRCA* variant dataset from Asian populations \[[@R60]\], and identified 35 overlapping variants (18 in *BRCA1* and 17 in *BRCA2*). Thirty-three (94.3%) of these overlapping variants were from Chinese ethnicity but not from other ethnicities ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}), confirming that these novel variants are mainland Chinese-specific. The presence of multiple novel variants provides a rich resource to identify new *BRCA* pathogenic mutations in mainland Chinese population.

In conclusion, our study indicates that *BRCA* variations are common in mainland Chinese familial breast and ovarian cancer patients. The absence of such information in current international BRCA databases appears to largely reflect the poor communication between Western and Chinese scientific communities. Our study also indicates while the prevalence of *BRCA* variation is similar to that of other populations, the spectrum of *BRCA* variation in Chinese patients differs substantially with the hot spots of *BRCA1* exons 11A, 11C, 11D, 24 and *BRCA2* exon 10. Except the c.981_982delAT in *BRCA1* exon 11A, there is no strong evidence showing the presence of common founder *BRCA* mutations in mainland Chinese patients, although such a possibility may exist in certain subpopulations of specific geographic regions or ethnic groups in mainland China.

MATERIALS AND METHODS {#s3}
=====================

Information sources {#s3_1}
-------------------

We searched two major Chinese scientific databases, China National Knowledge Infrastructure (CNKI) \[[@R63]\] and WanFang \[[@R16]\], which comprehensively collect information from Chinese academic journals, dissertations, conference proceedings, and patents, by using the key words "breast cancer", "*BRCA1* mutation", and "*BRCA2* mutation" in Chinese characters. From the identified publications, we excluded those of sporadic breast cancer, animals, and those about patients marked with "early diagnosis", "triple-negative", and "bilateral" but without age indication, "male", and from non-mainland Chinese. Using similar approaches but in English, we also searched the PubMed database to identify non-Chinese publications reporting *BRCA* mutations from mainland Chinese patients (Figure [1](#F1){ref-type="fig"}).

We applied multiple steps to ensure the reliability of the identified variants, including: 1) only including variants detected or validated by Sanger sequencing; 2) re-annotating all variants following HGVS nomenclature using the reference sequences U14680 for *BRCA1* and U43746 for *BRCA2*, regardless of original annotation; 3) using the BIC database (13-Mar-2015 version) as a reference to classify variants as known variants with BIC designation or novel variants without BIC designation; 4) excluding synonymous variants and un-interpretable variants from analysis; and 5) annotating novel variants by referring to their effects on coding changes in *BRCA1* and *BRCA2*. We used U14680 and U43746 as the reference sequences for *BRCA1* and *BRCA2* annotation, as they were used as the standard references by most of the cited publications and BIC database. However, different *BRCA* databases may use different *BRCA* reference sequences, which can generate differences for certain variants. For example, Clinvar database uses NM_007294 and NM_000059 as the references for *BRCA1 and BRCA2* (64). To facilitate data comparison with *BRCA* variants annotated by Clinvar database, we also included the variants annotated by using these two references ([Supplementary Tables 3](#SD2){ref-type="supplementary-material"}, [4](#SD3){ref-type="supplementary-material"}). All variants were annotated following HGVS nomenclature.

SUPPLEMENTARY TABLES {#s4}
====================
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BIC

:   Breast Cancer Information Core

BRCA1

:   breast cancer 1, early onset

BRCA2

:   breast cancer 2, early onset

HGVS

:   human genome variation society
